Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study

Edward R. Hammond, Rosa M. Crum, Glenn J. Treisman, Shruti H. Mehta, David B. Clifford, Ronald J. Ellis, Benjamin Gelman, Igor Grant, Scott L. Letendre, Christina M. Marra, Susan Morgello, David M. Simpson, Justin C. Mcarthur, The Charter Group For The Charter Group

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Major depressive disorder is the most common neuropsychiatric complication in human immunodeficiency virus (HIV) infections and is associated with worse clinical outcomes. We determined if detectable cerebrospinal fluid (CSF) HIV ribonucleic acid (RNA) at threshold ≥50 copies/ml is associated with increased risk of depression. The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohort is a six-center US-based prospective cohort with bi-annual follow-up of 674 participants. We fit linear mixed models (N = 233) and discrete-time survival models (N = 154; 832 observations) to evaluate trajectories of Beck Depression Inventory (BDI) II scores and the incidence of new-onset moderate-to-severe depressive symptoms (BDI ≥ 17) among participants on combination antiretroviral therapy (cART), who were free of depression at study entry and received a minimum of three CSF examinations over 2496 person-months follow-up. Detectable CSF HIV RNA (threshold ≥50 copies/ml) at any visit was associated with a 4.7-fold increase in new-onset depression at subsequent visits adjusted for plasma HIV RNA and treatment adherence; hazard ratio (HR) = 4.76, (95 % CI 1.58–14.3); P = 0.006. Depression (BDI) scores were 2.53 points higher (95 % CI 0.47–4.60; P = 0.02) over 6 months if CSF HIV RNA was detectable at a prior study visit in fully adjusted models including age, sex, race, education, plasma HIV RNA, duration and adherence of CART, and lifetime depression diagnosis by Diagnostic Statistical Manual (DSM-IV) criteria. Persistent CSF but not plasma HIV RNA is associated with an increased risk for new-onset depression. Further research evaluating the role of immune activation and inflammatory markers may improve our understanding of this association.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalJournal of NeuroVirology
DOIs
StateAccepted/In press - Jan 4 2016

Fingerprint

Cerebrospinal Fluid
Cohort Studies
HIV
Prospective Studies
RNA
Depression
Equipment and Supplies
Cohort Effect
Sex Education
Major Depressive Disorder
Virus Diseases
Research
Diagnostic and Statistical Manual of Mental Disorders
Linear Models
Therapeutics
Survival
Incidence

Keywords

  • Cerebrospinal fluid
  • Depression
  • Psychiatry
  • Viral load

ASJC Scopus subject areas

  • Virology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Neurology

Cite this

Hammond, E. R., Crum, R. M., Treisman, G. J., Mehta, S. H., Clifford, D. B., Ellis, R. J., ... For The Charter Group, T. C. G. (Accepted/In press). Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. Journal of NeuroVirology, 1-9. https://doi.org/10.1007/s13365-015-0416-1

Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. / Hammond, Edward R.; Crum, Rosa M.; Treisman, Glenn J.; Mehta, Shruti H.; Clifford, David B.; Ellis, Ronald J.; Gelman, Benjamin; Grant, Igor; Letendre, Scott L.; Marra, Christina M.; Morgello, Susan; Simpson, David M.; Mcarthur, Justin C.; For The Charter Group, The Charter Group.

In: Journal of NeuroVirology, 04.01.2016, p. 1-9.

Research output: Contribution to journalArticle

Hammond, ER, Crum, RM, Treisman, GJ, Mehta, SH, Clifford, DB, Ellis, RJ, Gelman, B, Grant, I, Letendre, SL, Marra, CM, Morgello, S, Simpson, DM, Mcarthur, JC & For The Charter Group, TCG 2016, 'Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study', Journal of NeuroVirology, pp. 1-9. https://doi.org/10.1007/s13365-015-0416-1
Hammond, Edward R. ; Crum, Rosa M. ; Treisman, Glenn J. ; Mehta, Shruti H. ; Clifford, David B. ; Ellis, Ronald J. ; Gelman, Benjamin ; Grant, Igor ; Letendre, Scott L. ; Marra, Christina M. ; Morgello, Susan ; Simpson, David M. ; Mcarthur, Justin C. ; For The Charter Group, The Charter Group. / Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. In: Journal of NeuroVirology. 2016 ; pp. 1-9.
@article{935ef5a2b55d41a489877236b293b6c0,
title = "Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study",
abstract = "Major depressive disorder is the most common neuropsychiatric complication in human immunodeficiency virus (HIV) infections and is associated with worse clinical outcomes. We determined if detectable cerebrospinal fluid (CSF) HIV ribonucleic acid (RNA) at threshold ≥50 copies/ml is associated with increased risk of depression. The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohort is a six-center US-based prospective cohort with bi-annual follow-up of 674 participants. We fit linear mixed models (N = 233) and discrete-time survival models (N = 154; 832 observations) to evaluate trajectories of Beck Depression Inventory (BDI) II scores and the incidence of new-onset moderate-to-severe depressive symptoms (BDI ≥ 17) among participants on combination antiretroviral therapy (cART), who were free of depression at study entry and received a minimum of three CSF examinations over 2496 person-months follow-up. Detectable CSF HIV RNA (threshold ≥50 copies/ml) at any visit was associated with a 4.7-fold increase in new-onset depression at subsequent visits adjusted for plasma HIV RNA and treatment adherence; hazard ratio (HR) = 4.76, (95 {\%} CI 1.58–14.3); P = 0.006. Depression (BDI) scores were 2.53 points higher (95 {\%} CI 0.47–4.60; P = 0.02) over 6 months if CSF HIV RNA was detectable at a prior study visit in fully adjusted models including age, sex, race, education, plasma HIV RNA, duration and adherence of CART, and lifetime depression diagnosis by Diagnostic Statistical Manual (DSM-IV) criteria. Persistent CSF but not plasma HIV RNA is associated with an increased risk for new-onset depression. Further research evaluating the role of immune activation and inflammatory markers may improve our understanding of this association.",
keywords = "Cerebrospinal fluid, Depression, Psychiatry, Viral load",
author = "Hammond, {Edward R.} and Crum, {Rosa M.} and Treisman, {Glenn J.} and Mehta, {Shruti H.} and Clifford, {David B.} and Ellis, {Ronald J.} and Benjamin Gelman and Igor Grant and Letendre, {Scott L.} and Marra, {Christina M.} and Susan Morgello and Simpson, {David M.} and Mcarthur, {Justin C.} and {For The Charter Group}, {The Charter Group}",
year = "2016",
month = "1",
day = "4",
doi = "10.1007/s13365-015-0416-1",
language = "English (US)",
pages = "1--9",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",

}

TY - JOUR

T1 - Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study

AU - Hammond, Edward R.

AU - Crum, Rosa M.

AU - Treisman, Glenn J.

AU - Mehta, Shruti H.

AU - Clifford, David B.

AU - Ellis, Ronald J.

AU - Gelman, Benjamin

AU - Grant, Igor

AU - Letendre, Scott L.

AU - Marra, Christina M.

AU - Morgello, Susan

AU - Simpson, David M.

AU - Mcarthur, Justin C.

AU - For The Charter Group, The Charter Group

PY - 2016/1/4

Y1 - 2016/1/4

N2 - Major depressive disorder is the most common neuropsychiatric complication in human immunodeficiency virus (HIV) infections and is associated with worse clinical outcomes. We determined if detectable cerebrospinal fluid (CSF) HIV ribonucleic acid (RNA) at threshold ≥50 copies/ml is associated with increased risk of depression. The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohort is a six-center US-based prospective cohort with bi-annual follow-up of 674 participants. We fit linear mixed models (N = 233) and discrete-time survival models (N = 154; 832 observations) to evaluate trajectories of Beck Depression Inventory (BDI) II scores and the incidence of new-onset moderate-to-severe depressive symptoms (BDI ≥ 17) among participants on combination antiretroviral therapy (cART), who were free of depression at study entry and received a minimum of three CSF examinations over 2496 person-months follow-up. Detectable CSF HIV RNA (threshold ≥50 copies/ml) at any visit was associated with a 4.7-fold increase in new-onset depression at subsequent visits adjusted for plasma HIV RNA and treatment adherence; hazard ratio (HR) = 4.76, (95 % CI 1.58–14.3); P = 0.006. Depression (BDI) scores were 2.53 points higher (95 % CI 0.47–4.60; P = 0.02) over 6 months if CSF HIV RNA was detectable at a prior study visit in fully adjusted models including age, sex, race, education, plasma HIV RNA, duration and adherence of CART, and lifetime depression diagnosis by Diagnostic Statistical Manual (DSM-IV) criteria. Persistent CSF but not plasma HIV RNA is associated with an increased risk for new-onset depression. Further research evaluating the role of immune activation and inflammatory markers may improve our understanding of this association.

AB - Major depressive disorder is the most common neuropsychiatric complication in human immunodeficiency virus (HIV) infections and is associated with worse clinical outcomes. We determined if detectable cerebrospinal fluid (CSF) HIV ribonucleic acid (RNA) at threshold ≥50 copies/ml is associated with increased risk of depression. The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohort is a six-center US-based prospective cohort with bi-annual follow-up of 674 participants. We fit linear mixed models (N = 233) and discrete-time survival models (N = 154; 832 observations) to evaluate trajectories of Beck Depression Inventory (BDI) II scores and the incidence of new-onset moderate-to-severe depressive symptoms (BDI ≥ 17) among participants on combination antiretroviral therapy (cART), who were free of depression at study entry and received a minimum of three CSF examinations over 2496 person-months follow-up. Detectable CSF HIV RNA (threshold ≥50 copies/ml) at any visit was associated with a 4.7-fold increase in new-onset depression at subsequent visits adjusted for plasma HIV RNA and treatment adherence; hazard ratio (HR) = 4.76, (95 % CI 1.58–14.3); P = 0.006. Depression (BDI) scores were 2.53 points higher (95 % CI 0.47–4.60; P = 0.02) over 6 months if CSF HIV RNA was detectable at a prior study visit in fully adjusted models including age, sex, race, education, plasma HIV RNA, duration and adherence of CART, and lifetime depression diagnosis by Diagnostic Statistical Manual (DSM-IV) criteria. Persistent CSF but not plasma HIV RNA is associated with an increased risk for new-onset depression. Further research evaluating the role of immune activation and inflammatory markers may improve our understanding of this association.

KW - Cerebrospinal fluid

KW - Depression

KW - Psychiatry

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=84952915650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952915650&partnerID=8YFLogxK

U2 - 10.1007/s13365-015-0416-1

DO - 10.1007/s13365-015-0416-1

M3 - Article

C2 - 26727907

AN - SCOPUS:84952915650

SP - 1

EP - 9

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

ER -